Article Contents ::
Details About Generic Salt :: Melphalan
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
| 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS |
| MELPHALAN |
| ALKYLATOR | ANTI-NEOPLASTIC |
| PK: A: Variable & incomplete (PO) D: 0.5-0.6 L/kg (Vd) M: Hepatic E: Feces (20%-50%), urine (~10% as unchanged drug) |
|
Indications & Dose: MULTIPLE MYELOMA PO Adult Initially 6mg/day for 2-3 wk, then discontinue drug for up to 4 wk or until WBC & platelet counts increase, MD 2mg/day as hematologic recovery begins | IV Adult 16mg/m2 over 15-30min q2wk intervals for 4 doses, then administer at 4wk intervals after adequate hematologic recovery | OVARIAN CARCINOMA PO Adult 0.2mg/kg/day 5 days, repeat q4-5wk |
| Contra: Hypersensitivity, patients whose disease was resistant to prior melphalan therapy
Precautions: Bone marrow suppression, who received prior/concurrent chemotherapy/irradiation, renal impairment ADR: Serious: Myelosuppression, blood disorders, secondary malignancy, anaphylaxis, irreversible bone marrow failure, hepatic veno-occlusive disease, suppression of ovarian function in premenopausal women, temporary/permanent sterility in male patients, Others: skin ulceration, necrosis, GI disturbances, diarrhea, vomiting, stomatitis, vasculitis DDI: Serious Interferon α decreases drug AUC & increases its cytotoxicity, Ciclosporin nephrotoxic effects may increases, Cimetidine reduces drug bioavailability Diet: On an empty stomach Monitor: CBC with differential & platelet count, serum electrolytes, serum uric acid |
